Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma

Tohru Utsunomiya, Hiroshi Inoue, Fumiaki Tanaka, Hiroshi Yamaguchi, Mitsuhiko Ohta, Masahiro Okamoto, Koshi Mimori, Masaki Mori

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Cancer-testis antigens (CTA), such as MAGE, are selectively expressed in various types of human neoplasms but not in normal tissues other than testis. This characteristic feature of CTA makes them promising antigens for cancer-specific immunotherapy. Methods: We investigated the expression of five genes, including MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4, in 20 surgical samples of intrahepatic cholangiocarcinomas (IHCC) using reverse transcription-polymerase chain reaction. To visualize the localization of MAGE proteins, we performed immunohistochemical studies. Furthermore, the correlation between the CTA expression and DNA methylation status was studied in three bile duct cancer cell lines. Results: Expression of MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4 was recognized in 4, 4, 2, 6, and 3 of all 20 cases, respectively. In contrast, the expressions of five genes were not recognized at all in the corresponding normal tissues. In 10 cases (50%), the tumors expressed at least one of the five CTA. An immunohistochemical analysis of MAGE proteins demonstrated homogenous or focal distributions in cytoplasm of the IHCC. Using a demethylating agent, MAGE-1, NY-ESO-1, SCP-1, and SSX-4 were induced in two of three cell lines, whereas MAGE-3 was not. Conclusions: Half of the tumor tissues of IHCC expressed at least one of the CTA. Some of the patients with IHCC, therefore, should be candidates for potentially useful cancer-specific immunotherapy.

Original languageEnglish
Pages (from-to)934-940
Number of pages7
JournalAnnals of Surgical Oncology
Volume11
Issue number10
DOIs
Publication statusPublished - Dec 1 2004

Fingerprint

Cholangiocarcinoma
Testicular Neoplasms
Antigens
Genes
Neoplasms
Immunotherapy
Bile Duct Neoplasms
Gene Expression
Cell Line
DNA Methylation
Reverse Transcription
Testis
Cytoplasm
Proteins
Polymerase Chain Reaction
SCP 1

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma. / Utsunomiya, Tohru; Inoue, Hiroshi; Tanaka, Fumiaki; Yamaguchi, Hiroshi; Ohta, Mitsuhiko; Okamoto, Masahiro; Mimori, Koshi; Mori, Masaki.

In: Annals of Surgical Oncology, Vol. 11, No. 10, 01.12.2004, p. 934-940.

Research output: Contribution to journalArticle

Utsunomiya T, Inoue H, Tanaka F, Yamaguchi H, Ohta M, Okamoto M et al. Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma. Annals of Surgical Oncology. 2004 Dec 1;11(10):934-940. https://doi.org/10.1245/ASO.2004.01.029
Utsunomiya, Tohru ; Inoue, Hiroshi ; Tanaka, Fumiaki ; Yamaguchi, Hiroshi ; Ohta, Mitsuhiko ; Okamoto, Masahiro ; Mimori, Koshi ; Mori, Masaki. / Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma. In: Annals of Surgical Oncology. 2004 ; Vol. 11, No. 10. pp. 934-940.
@article{6c6ec60b65d4475b802647476c15cc15,
title = "Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma",
abstract = "Background: Cancer-testis antigens (CTA), such as MAGE, are selectively expressed in various types of human neoplasms but not in normal tissues other than testis. This characteristic feature of CTA makes them promising antigens for cancer-specific immunotherapy. Methods: We investigated the expression of five genes, including MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4, in 20 surgical samples of intrahepatic cholangiocarcinomas (IHCC) using reverse transcription-polymerase chain reaction. To visualize the localization of MAGE proteins, we performed immunohistochemical studies. Furthermore, the correlation between the CTA expression and DNA methylation status was studied in three bile duct cancer cell lines. Results: Expression of MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4 was recognized in 4, 4, 2, 6, and 3 of all 20 cases, respectively. In contrast, the expressions of five genes were not recognized at all in the corresponding normal tissues. In 10 cases (50{\%}), the tumors expressed at least one of the five CTA. An immunohistochemical analysis of MAGE proteins demonstrated homogenous or focal distributions in cytoplasm of the IHCC. Using a demethylating agent, MAGE-1, NY-ESO-1, SCP-1, and SSX-4 were induced in two of three cell lines, whereas MAGE-3 was not. Conclusions: Half of the tumor tissues of IHCC expressed at least one of the CTA. Some of the patients with IHCC, therefore, should be candidates for potentially useful cancer-specific immunotherapy.",
author = "Tohru Utsunomiya and Hiroshi Inoue and Fumiaki Tanaka and Hiroshi Yamaguchi and Mitsuhiko Ohta and Masahiro Okamoto and Koshi Mimori and Masaki Mori",
year = "2004",
month = "12",
day = "1",
doi = "10.1245/ASO.2004.01.029",
language = "English",
volume = "11",
pages = "934--940",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma

AU - Utsunomiya, Tohru

AU - Inoue, Hiroshi

AU - Tanaka, Fumiaki

AU - Yamaguchi, Hiroshi

AU - Ohta, Mitsuhiko

AU - Okamoto, Masahiro

AU - Mimori, Koshi

AU - Mori, Masaki

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Background: Cancer-testis antigens (CTA), such as MAGE, are selectively expressed in various types of human neoplasms but not in normal tissues other than testis. This characteristic feature of CTA makes them promising antigens for cancer-specific immunotherapy. Methods: We investigated the expression of five genes, including MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4, in 20 surgical samples of intrahepatic cholangiocarcinomas (IHCC) using reverse transcription-polymerase chain reaction. To visualize the localization of MAGE proteins, we performed immunohistochemical studies. Furthermore, the correlation between the CTA expression and DNA methylation status was studied in three bile duct cancer cell lines. Results: Expression of MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4 was recognized in 4, 4, 2, 6, and 3 of all 20 cases, respectively. In contrast, the expressions of five genes were not recognized at all in the corresponding normal tissues. In 10 cases (50%), the tumors expressed at least one of the five CTA. An immunohistochemical analysis of MAGE proteins demonstrated homogenous or focal distributions in cytoplasm of the IHCC. Using a demethylating agent, MAGE-1, NY-ESO-1, SCP-1, and SSX-4 were induced in two of three cell lines, whereas MAGE-3 was not. Conclusions: Half of the tumor tissues of IHCC expressed at least one of the CTA. Some of the patients with IHCC, therefore, should be candidates for potentially useful cancer-specific immunotherapy.

AB - Background: Cancer-testis antigens (CTA), such as MAGE, are selectively expressed in various types of human neoplasms but not in normal tissues other than testis. This characteristic feature of CTA makes them promising antigens for cancer-specific immunotherapy. Methods: We investigated the expression of five genes, including MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4, in 20 surgical samples of intrahepatic cholangiocarcinomas (IHCC) using reverse transcription-polymerase chain reaction. To visualize the localization of MAGE proteins, we performed immunohistochemical studies. Furthermore, the correlation between the CTA expression and DNA methylation status was studied in three bile duct cancer cell lines. Results: Expression of MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4 was recognized in 4, 4, 2, 6, and 3 of all 20 cases, respectively. In contrast, the expressions of five genes were not recognized at all in the corresponding normal tissues. In 10 cases (50%), the tumors expressed at least one of the five CTA. An immunohistochemical analysis of MAGE proteins demonstrated homogenous or focal distributions in cytoplasm of the IHCC. Using a demethylating agent, MAGE-1, NY-ESO-1, SCP-1, and SSX-4 were induced in two of three cell lines, whereas MAGE-3 was not. Conclusions: Half of the tumor tissues of IHCC expressed at least one of the CTA. Some of the patients with IHCC, therefore, should be candidates for potentially useful cancer-specific immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=16544375969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544375969&partnerID=8YFLogxK

U2 - 10.1245/ASO.2004.01.029

DO - 10.1245/ASO.2004.01.029

M3 - Article

C2 - 15466353

AN - SCOPUS:16544375969

VL - 11

SP - 934

EP - 940

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -